Systemic anti-cancer therapy: management options for people with non-squamous (adenocarcinoma, large cell undifferentiated) carcinoma and non-small-cell carcinoma (non-otherwise specified)

- **EGFR-TK positive**
  - Afatinib (TA310) or Erlotinib (TA258) or Gefitinib (TA192)
  - Pemetrexed maintenance (TA402 or TA190)
  - Atezolizumab (no PD-L1 expression needed) (TA520)
  - Nivolumab (if PD-L1 >1%) (TA484)
  - Pembrolizumab combination (TA557)
- **ALK positive**
  - Ceritinib (TA500)
  - Alectinib (TA536)
  - Crizotinib (TA406)
  - Brigatinib (TA571)
  - Ceritinib (TA395)
  - Pembrolizumab (TA531)
- **ROS-1 positive**
  - Crizotinib (TA529)
- **PD-L1 <50%**
  - No gene mutation or fusion protein
  - Pembrolizumab combination (TA557)
- **PD-L1 ≥50%**
  - Pembrolizumab (TA531)
- **T790M positive?**
  - Yes
  - Osimertinib (TA416)
  - Pembrolizumab (if PD-L1 >1%) (TA428)
  - Nivolumab (if PD-L1 >1%) (TA484)
  - Disease progression
- **No gene mutation or fusion protein**
  - Pembrolizumab (TA531)


This is a summary of the recommendations on management options for people with non-squamous and non-small-cell carcinoma from the NICE guideline on lung cancer (www.nice.org.uk/guidance/NG122). See the NICE Pathway for an integrated view of all NICE recommendations on lung cancer, and see technology appraisals for information on eligibility, patient access schemes and more. © NICE 2019. All rights reserved. Subject to Notice of rights.